Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts

Journal of Heart and Lung Transplantation

Volumn 29, Issue 5, 2010, Pages 562-567

  Kosuge, Hisanori ^a   Ishihara, Takashi ^a   Haraguchi, Go ^a   Maejima, Yasuhiro ^a   Okada, Hiroyuki ^a   Saiki, Hitoshi ^a   Suzuki, Jun ichi ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

arteriosclerosis; inflammation; pharmacology; smooth muscle cell; transplantation

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE I; GAMMA INTERFERON; GELATINASE A; INTERLEUKIN 10; INTERLEUKIN 15; MESSENGER RNA; TELMISARTAN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELL DIVISION; CORONARY ARTERY DISEASE; CYTOKINES; GRAFT REJECTION; HEART TRANSPLANTATION; HYPERPLASIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; TRANSPLANTATION, HOMOLOGOUS; TUNICA MEDIA;

EID: 77950520086     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.11.001     Document Type: Article

References (33)

1. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879
2. Weis M., and von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 96 (1997) 2069-2077
3. Berk B.C., and Corson M.A. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 80 (1997) 607-616
4. de Gasparo M., Catt K.J., Inagami T., et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
5. Yousufuddin M., Cook D.J., Starling R.C., et al. Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol 43 (2004) 1565-1573
6. Yousufuddin M., Haji S., Starling R.C., et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J 25 (2004) 377-385
7. Yamani M.H., Cook D.J., Rodriguez E.R., et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 25 (2006) 1283-1289
8. Yamamoto T., Sata M., Fukuda D., et al. The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy. J Surg Res 132 (2006) 62-68
9. Richter M., Skupin M., Grabs R., et al. New approach in the therapy of chronic rejection?. ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant 19 (2000) 1047-1055
10. Yamamoto T., Sata M., Fukuda D., et al. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol 100 (2005) 84-91
11. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
12. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
13. Chen Z., Ishibashi S., Perrey S., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21 (2001) 372-377
14. Asakawa M., Takano H., Nagai T., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
15. Yuan Z., Liu Y., Zhang J., et al. Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 59 (2003) 685-694
16. Law R.E., Meehan W.P., Xi X.P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98 (1996) 1897-1905
17. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 (2000) 1364-1371
18. Marx N., Schonbeck U., Lazar M.A., et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 (1998) 1097-1103
19. de Dios S.T., Bruemmer D., Dilley R.J., et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107 (2003) 2548-2550
20. Pasceri V., Wu H.D., Willerson J.T., et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
21. Wang N., Verna L., Chen N.G., et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 277 (2002) 34176-34181
22. Kosuge H., Haraguchi G., Koga N., et al. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113 (2006) 2613-2622
23. Isobe M., Haber E., and Khaw B.A. Early detection of rejection and assessment of cyclosporine therapy by indium-111 antimyosin imaging in mouse heart allografts. Circulation 84 (1991) 1246-1255
24. Suzuki J., Cole S.E., Batirel S., et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 3 (2003) 968-976
25. Eich D.M., Nestler J.E., Johnson D.E., et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87 (1993) 261-269
26. Shimizu K., Schönbeck U., Mach F., et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 165 (2000) 3506-3518
27. Corthorn J., Rey S., Chacon C., et al. Spatio-temporal expression of MMP-2, MMP-9 and tissue kallikrein in uteroplacental units of the pregnant guinea-pig (Cavia porcellus). Reprod Biol Endocrinol 5 (2007) 27
28. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17 (2006) 889-899
29. Zezina L., Larsson E., and Fellstrom B. Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. Transplant Immunol 8 (2001) 245-251
30. Tsuda M., Iwai M., Li J.M., et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45 (2005) 545-551
31. Furukawa Y., Mandelbrot D.A., Libby P., et al. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am J Pathol 157 (2000) 473-484
32. Zheng X.X., Gao W., Donskoy E., et al. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 81 (2006) 109-116
33. Tsukioka K., Suzuki J., Fujimori M., et al. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 56 (2002) 472-478